Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Integra Lifesciences (IART) Stock Price & Analysis
213 Followers
IART Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.36 - $50.78
Previous Close$24.91
Volume2.27M
Average Volume (3M)992.77K
Market Cap
$1.96B
Enterprise Value$3.34B
Total Cash (Recent Filing)$663.10M
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)49.1
Beta1.12
Next Earnings
Jul 24, 2024EPS Estimate
$0.62Last Dividend Ex-Date
Jul 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding78,799,694
10 Day Avg. Volume1,843,082
30 Day Avg. Volume992,769
Standard Deviation0.10
R-Squared0.41
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.66
Price to Sales (P/S)5.15
Price to Cash Flow (P/CF)8.40
P/FCF Ratio7.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda15.10
Forecast
1Y Price Target
$31.63Price Target Upside25.02% Upside
Rating ConsensusHold
Number of Analyst Covering10
Integra Lifesciences News
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactThe recently closed Acclarent deal has contributed to an increase in the 2024 revenue estimate.
Earnings PerformanceIntegra LifeSciences' first-quarter sales were above expectations, aligning with market estimates.
Operational EfficiencyGross margin is expected to improve modestly with more improvement anticipated in the upcoming years.
Bears Say
Financial PerformanceRevenue and adjusted EPS falling below consensus estimates, alongside guidance for weaker upcoming quarters, may erode investor confidence and signal underlying financial weaknesses.
Leadership UncertaintyThe CEO's impending retirement introduces leadership uncertainty at a time when the company is facing significant operational hurdles.
Operational ChallengesThe restart of the Boston facility is not expected in 2024, leading to sustained operational challenges and investor concerns over the company's ability to meet future revenue projections.
---
Ownership Overview
28.05% Insiders
39.71% Mutual Funds
25.17% Other Institutional Investors
7.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $22.36 and its highest was $50.78 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Currently, no data Available
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Jul 24, 2024 which is in 75 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on May 06, 2024. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.552 by -$0.002.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. pays a Notavailable dividend of $3.18 which represents an annual dividend yield of N/A. See more information on Integra Lifesciences Holdings Corp. dividends here
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is $0.62.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 78,799,690 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.55 in its last earnings report, missing expectations of $0.552. Following the earnings report the stock price went down -19.903%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Among the largest hedge funds holding Integra Lifesciences Holdings Corp.’s share is Deerfield Management Company, LP. It holds Integra Lifesciences Holdings Corp.’s shares valued at 49M.
---
Integra Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$31.63 (25.02% Upside)
$31.63 (25.02% Upside)
Hedge Fund Trend
Decreased
By 92.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.54%
12-Months-Change
Fundamentals
Return on Equity
2.46%
Trailing 12-Months
Asset Growth
8.97%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
---
IART Company Deck
---
IART Earnings Call
Q1 2024
0:00 / 0:00
---
IART Stock 12 Month Forecast
Average Price Target
$31.63
▲(25.02% Upside)
Technical Analysis
Merit Medical Systems
―
Smith & Nephew Snats
―
Teleflex
―
West Pharmaceutical Services
―
Best Analysts Covering IART
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+27.90%
reiterated a sell rating 5 days ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +27.90% per trade.
---